Shares of Zydus Lifesciences Ltd fell 1% after touching a day’s high of Rs 1,002 on 7th October, despite the company announcing on Monday (6th October) that it has received a Notice of Compliance (NOC) from Health Canada for its generic Liothyronine tablets in 5 mcg and 25 mcg strengths.

Liothyronine, a synthetic version of the thyroid hormone T3, is used to treat hypothyroidism. Zydus will manufacture the tablets at its Ahmedabad SEZ facility.

According to IQVIA data for June 2025, the product achieved annual sales of 10.9 million Canadian dollars in Canada. With the approval, Zydus and its subsidiaries can now market the drug in Canada. This will strengthen their presence in the North American generics market.

Separately, Zydus also received final approval from the USFDA for Deflazacort Oral Suspension (22.75 mg/mL), a generic version of Emflaza. This drug is used to treat Duchenne Muscular Dystrophy (DMD) in patients aged five and above. The drug, which helps reduce inflammation and control an overactive immune response, will be produced at the company’s Doppel facility in Italy.

With this approval, Zydus’ total USFDA approvals have reached 424. This is out of 487 abbreviated new drug applications (ANDAs) filed since FY 2003-04.

At 11:33 AM, the shares of Zydus Lifesciences were trading 0.85% lower at Rs 986.15 on NSE.

Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!